Skip to content

Clinical trials

Phase 2 Leukemia, Myeloid, Acute trials in Germany

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myeloid, Acute Phase: Phase 2 Country / region: Germany Clear all

72 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20022
20032
20044
20051
20062
20084
20096
20101
20117
20123
20133
20142
20156
20164
20172
20182
20196
20203
20212
20232
20242
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed46
Terminated11
Unknown status5
Active, not recruiting4
Recruiting4
Not yet recruiting1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Technische Universität Dresden11
Novartis Pharmaceuticals7
University of Ulm5
Boehringer Ingelheim3
Heinrich-Heine University, Duesseldorf3
University Hospital Muenster3
Celgene2
European Organisation for Research and Treatment of Cancer - EORTC2
GWT-TUD GmbH2
Kiadis Pharma2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myeloid, Acute72
Myelodysplastic Syndromes16
Precursor Cell Lymphoblastic Leukemia-Lymphoma10
Recurrence7
Leukemia, Myelomonocytic, Chronic6
Leukemia5
Neoplasms5
Hematologic Neoplasms4
Myeloproliferative Disorders4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive3

Trials

Showing 1 to 25 of 72. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.